Sverige - svenska - Läkemedelsverket (Medical Products Agency)

medartuum ab - metylfenidathydroklorid - kapsel med modifierad frisättning, hård - 60 mg - sockersfärer hjälpämne; natriumlaurilsulfat hjälpämne; sorbinsyra hjälpämne; metylfenidathydroklorid 30 mg aktiv substans; metylfenidathydroklorid 30 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

medartuum ab - metylfenidathydroklorid - kapsel med modifierad frisättning, hård - 50 mg - sockersfärer hjälpämne; sorbinsyra hjälpämne; metylfenidathydroklorid 25 mg aktiv substans; metylfenidathydroklorid 25 mg aktiv substans; natriumlaurilsulfat hjälpämne

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

medartuum ab - metylfenidathydroklorid - kapsel med modifierad frisättning, hård - 30 mg - sockersfärer hjälpämne; sorbinsyra hjälpämne; natriumlaurilsulfat hjälpämne; metylfenidathydroklorid 15 mg aktiv substans; metylfenidathydroklorid 15 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

medartuum ab - metylfenidathydroklorid - kapsel med modifierad frisättning, hård - 40 mg - natriumlaurilsulfat hjälpämne; sorbinsyra hjälpämne; sockersfärer hjälpämne; metylfenidathydroklorid 20 mg aktiv substans; metylfenidathydroklorid 20 mg aktiv substans

Europeiska unionen - svenska - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - antineoplastiska medel - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.

Europeiska unionen - svenska - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - tocilizumab - arthritis, rheumatoid; cytokine release syndrome; arthritis, juvenile rheumatoid; covid-19 virus infection; giant cell arteritis - immunsuppressiva - tyenne, in combination with methotrexate (mtx), is indicated for- the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx. - the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists. in these patients, tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tocilizumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. tyenne is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. tyenne can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx. tyenne in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tyenne is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older. tyenne is indicated for the treatment of giant cell arteritis (gca) in adult patients.

Europeiska unionen - svenska - EMA (European Medicines Agency)

paion deutschland gmbh - angiotensin ii-acetat - hypotension; shock - agenter som verkar på renin-angiotensinsystemet - giapreza är indicerat för behandling av svårbehandlad hypotension hos vuxna med septisk eller andra distributiv chock som fortfarande hypotensiva trots adekvat volym återlämnande och tillämpning av katekolaminer och andra tillgängliga kärlsammandragande behandlingar.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

fresenius medical care nephrologica deutschland gmbh - calciumpolystyrensulfonat - pulver till oral/rektal suspension - sackaros hjälpämne; calciumpolystyrensulfonat 759 - 949 mg aktiv substans - polystyrensulfonat

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

fresenius medical care nephrologica deutschland gmbh - calciumpolystyrensulfonat - pulver till oral/rektal suspension i dospåse - 15 g - calciumpolystyrensulfonat 14,617 g aktiv substans; mannitol hjälpämne - polystyrensulfonat

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

fresenius medical care deutschland gmbh - kalciumkloriddihydrat - infusionsvätska, lösning - 100 mmol/l - kalciumkloriddihydrat 14,7 g aktiv substans